Our Mission
Who we are
MetaHeps® has an ex-vivo blood test to exclude or clearly identify DILI in a patient with liver injury. It can also identify the causal drug of the DILI especially in a complex polymedication situation. MetaHeps thereby helps BioPharmaceutical companies and CROs to solve the risks of DILI for drugs in clinical development and in the market. All in an unrivalled way.
Patient Risks
The Clinical Challenge
Drug Induced Liver Injury (DILI) or disease is an uncommon but potentially fatal injury or disease of the liver, which can be caused by prescription medicines, over the counter (OTC) medicines, vitamins, food additives, herbs and herbal medicines, recreational drugs and environmental toxins.
Biopharma Risks
Solutions for BioPharma Industry
Drug Induced Liver Injury is a major challenge for pharmacovigilance and its risks and consequences are often undervalued. Equally difficult is the diagnosis, especially identifying the causative drug, or combination of drugs resulting in DILI. Therapeutic measures often follow the trial and error principle.
Our Solution
The MetaHeps Technology
MetaHeps has developed and offers the first and only in-vitro test to clearly identify the cause of suspected DILI.